Financing Startups: F2G Secures $100M Series H to Advance Fungal Infection Therapy
F2G's Series H Financing
F2G, located in Manchester, UK, has successfully raised $100 million in a Series H funding round just over a year after facing a Complete Response Letter (CRL) from the FDA concerning their investigational drug for fungal infections, olsufim. This substantial funding is structured in tranches, beginning with $62.5 million, paired with an additional $37.5 million contingent on future milestones. Such private financing rounds are rare in the current market climate, making this a notable achievement.
Regulatory Path Forward
The CEO of F2G, Francesco Maria Lavino, expressed optimism about their engagement with the FDA, referencing multiple meetings since the CRL. The company aims to reapply for FDA approval toward the end of 2025, anticipating a potential green light by mid-2026. With a focus on rare diseases, F2G positions itself in a niche market for fungal treatment, targeting patients with limited options.
- Potential market expansion post-approval
- Investments from new and existing backers
- Increased focus on rare fungal infections
Conclusion of Funding Insights
The acquired financing not only supports F2G in its regulatory efforts but also highlights the significance of startups in the healthcare space. As F2G prepares for further trials, their commitment to advancing treatments for immunocompromised patients remains at the forefront of their mission.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.